An Israeli breakthrough in the treatment of cancer has the international medical community taking notice. Developed by Tel Aviv University Professors Rimona Margalit and Dan Peer, this novel drug-delivery platform involves the use of “GAGomers,” a new class of nanoparticles (coated with glycosaminoglycan, or GAGs, a polysugar) that specifically target tumors and blood cancers based on a biomarker expressed on malignant tissue.
